Skip to main navigation Skip to search Skip to main content

CRISPR/Cas9-based targeting of fluorescent reporters to human iPSCs to isolate atrial and ventricular-specific cardiomyocytes

  • Orlando Chirikian
  • , William R. Goodyer
  • , Elda Dzilic
  • , Vahid Serpooshan
  • , Jan W. Buikema
  • , Wesley McKeithan
  • , Hao Di Wu
  • , Guang Li
  • , Soah Lee
  • , Markus Merk
  • , Francisco Galdos
  • , Aimee Beck
  • , Alexandre J.S. Ribeiro
  • , Sharon Paige
  • , Mark Mercola
  • , Joseph C. Wu
  • , Beth L. Pruitt
  • , Sean M. Wu
  • Stanford University
  • California State University Channel Islands
  • University of California at Santa Barbara
  • Division of Cardiology
  • Technical University of Munich
  • Utrecht University

Research output: Contribution to journalArticlepeer-review

Abstract

Generating cardiomyocytes (CMs) from human induced pluripotent stem cells (hiPSCs) has represented a significant advance in our ability to model cardiac disease. Current differentiation protocols, however, have limited use due to their production of heterogenous cell populations, primarily consisting of ventricular-like CMs. Here we describe the creation of two chamber-specific reporter hiPSC lines by site-directed genomic integration using CRISPR-Cas9 technology. In the MYL2-tdTomato reporter, the red fluorescent tdTomato was inserted upstream of the 3′ untranslated region of the Myosin Light Chain 2 (MYL2) gene in order faithfully label hiPSC-derived ventricular-like CMs while avoiding disruption of endogenous gene expression. Similarly, in the SLN-CFP reporter, Cyan Fluorescent Protein (CFP) was integrated downstream of the coding region of the atrial-specific gene, Sarcolipin (SLN). Purification of tdTomato+ and CFP+ CMs using flow cytometry coupled with transcriptional and functional characterization validated these genetic tools for their use in the isolation of bona fide ventricular-like and atrial-like CMs, respectively. Finally, we successfully generated a double reporter system allowing for the isolation of both ventricular and atrial CM subtypes within a single hiPSC line. These tools provide a platform for chamber-specific hiPSC-derived CM purification and analysis in the context of atrial- or ventricular-specific disease and therapeutic opportunities.

Original languageEnglish
Article number3026
JournalScientific Reports
Volume11
Issue number1
DOIs
StatePublished - Dec 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'CRISPR/Cas9-based targeting of fluorescent reporters to human iPSCs to isolate atrial and ventricular-specific cardiomyocytes'. Together they form a unique fingerprint.

Cite this